並列タイトル等9-ING-41(GSK-3阻害剤)は、腎癌に対して単剤および併用療法として有効である
一般注記Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological processes including cancer. GSK-3 has two isoforms, GSK-3αand GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aimed to investigate the antitumor effects of9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3β inhibitor active in patients with advanced cancer. In renal cancer cell lines, treatment with 9-ING-41 alone induced cell cycle arrest and apoptosis, and autophagy inhibitors increased the antitumor effects of 9-ING-41 when used in combination. Treatment with 9-ING-41 potentiated the antitumor effects of targeted therapeutics and increased the cytotoxic effects of cytokine-activated immune cells on renal cancer cell lines. These results provided a compelling rationale for the inclusion of patients with renal cancer in studies of 9-ING-41, both as a single agent and in combination with current standard therapies.
International Journal of Molecular Medicine. 2020, 45(2), 315-323.
新大院博(医)甲第931号
DOIinfo:doi/10.3892/ijmm.2019.4427
コレクション（個別）国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
受理日（W3CDTF）2020-09-07T06:04:08+09:00
連携機関・データベース国立国会図書館 : 国立国会図書館デジタルコレクション